Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase I clinical trial of novel cervical dysplasia Rx from StressGen

Feb. 3, 1999

SWOG phase II study of safety and efficacy of rhIL-4 in malignant melanoma

Jan. 25, 1999

Polish authorities allow phase II testing of Multikine

Jan. 15, 1999

Health Canada approves new indication for Proleukin

Jan. 12, 1999

Proleukin receives orphan drug status for two new indications

Jan. 7, 1999

Anticancer immunotoxin available for licensing from NIH

Jan. 4, 1999

Promising phase III trial results presented for Coulter's lead cancer therapy

Dec. 29, 1998

Merck obtains option to expand MDX-447 collaboration with Medarex

Dec. 29, 1998

FDA grants fast track designation for OvaRex MAb

Dec. 22, 1998

Cell Genesys and Japan Tobacco enter worldwide collaboration for GVAX cancer vaccine

Dec. 22, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.